CureVac's COVID vaccine enters EMA's rolling review

The European Medicines Agency (EMA) has begun a rolling review of another vaccine against COVID-19, the agency announced Friday.

EMA’s human medicines committee (CHMP) will review available data on CureVac’s messenger RNA (mRNA) vaccine CVnCoV. The vaccine is currently being tested in a Phase 2b/3 clinical trial of about 36,000 participants in Germany, as well as in a German Phase 3 trial involving healthcare workers.